Keshava Kumar

发表

CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2018, Leukemia research.

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

H. Döhner, H. Dombret, B. Skikne, 2020, The New England journal of medicine.

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

B. Skikne, G. Garcia-Manero, S. Gore, 2016 .

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

H. Döhner, H. Dombret, B. Skikne, 2019 .

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

B. Skikne, G. Garcia-Manero, S. Gore, 2015, PloS one.

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

H. Döhner, F. Thol, H. Dombret, 2020 .

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

H. Döhner, H. Dombret, B. Skikne, 2020 .

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

B. Skikne, S. Kambhampati, A. Oriol, 2020 .

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

T. Chevassut, H. Dombret, B. Skikne, 2020 .

Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome.

P. Hanno, J. Nickel, Keshava Kumar, 2012, Urology.

Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

B. Skikne, G. Garcia-Manero, S. Gore, 2012 .

Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2012 .

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

B. Skikne, S. Kambhampati, G. Garcia-Manero, 2015, Leukemia.